share_log

Downgrade: Here's How Analysts See Haohua Chemical Science & Technology Corp., Ltd. (SHSE:600378) Performing In The Near Term

Downgrade: Here's How Analysts See Haohua Chemical Science & Technology Corp., Ltd. (SHSE:600378) Performing In The Near Term

降級:以下是分析師對昊華化學科技股份有限公司(SHSE: 600378)短期表現的看法
Simply Wall St ·  05/03 08:09

One thing we could say about the analysts on Haohua Chemical Science & Technology Corp., Ltd. (SHSE:600378) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organization. Both revenue and earnings per share (EPS) estimates were cut sharply as the analysts factored in the latest outlook for the business, concluding that they were too optimistic previously.

關於昊華化學科技股份有限公司(SHSE: 600378)的分析師,我們可以說一件事——他們並不樂觀,因爲他們剛剛對該組織的短期(法定)預測進行了重大負面修正。由於分析師將最新的業務前景考慮在內,得出結論,他們此前過於樂觀,因此收入和每股收益(EPS)的預期均大幅下調。

After this downgrade, Haohua Chemical Science & Technology's dual analysts are now forecasting revenues of CN¥9.0b in 2024. This would be a huge 21% improvement in sales compared to the last 12 months. Statutory earnings per share are presumed to leap 31% to CN¥1.16. Before this latest update, the analysts had been forecasting revenues of CN¥11b and earnings per share (EPS) of CN¥1.45 in 2024. It looks like analyst sentiment has declined substantially, with a substantial drop in revenue estimates and a real cut to earnings per share numbers as well.

在這次降級之後,皓華化學科技的雙重分析師現在預測2024年的收入爲90億元人民幣。與過去12個月相比,這將使銷售額大幅增長21%。預計每股法定收益將增長31%,至1.16元人民幣。在最新更新之前,分析師一直預測2024年的收入爲110億元人民幣,每股收益(EPS)爲1.45元人民幣。看來分析師的情緒已大幅下降,收入預期大幅下降,每股收益數字也有所下降。

earnings-and-revenue-growth
SHSE:600378 Earnings and Revenue Growth May 3rd 2024
SHSE: 600378 收益和收入增長 2024 年 5 月 3 日

It'll come as no surprise then, to learn that the analysts have cut their price target 12% to CN¥37.12.

因此,得知分析師已將目標股價下調12%至37.12元人民幣也就不足爲奇了。

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Haohua Chemical Science & Technology's rate of growth is expected to accelerate meaningfully, with the forecast 21% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 15% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 16% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Haohua Chemical Science & Technology to grow faster than the wider industry.

當然,看待這些預測的另一種方法是將它們與行業本身聯繫起來。從最新估計中可以明顯看出,昊華化學科技的增長率預計將大幅加速,預計到2024年底的年化收入增長率爲21%,將明顯快於過去五年中每年15%的歷史增長。相比之下,同行業的其他公司預計收入每年將增長16%。顯而易見,儘管增長前景比最近更加光明,但分析師也預計,皓華化學科技的增長速度將超過整個行業。

The Bottom Line

底線

The most important thing to take away is that analysts cut their earnings per share estimates, expecting a clear decline in business conditions. Unfortunately, analysts also downgraded their revenue estimates, although our data indicates revenues are expected to perform better than the wider market. After such a stark change in sentiment from analysts, we'd understand if readers now felt a bit wary of Haohua Chemical Science & Technology.

要了解的最重要的一點是,分析師下調了每股收益預期,預計業務狀況將明顯下降。不幸的是,分析師也下調了收入預期,儘管我們的數據顯示收入表現預計將好於整個市場。在分析師的觀點發生了如此明顯的變化之後,我們可以理解讀者現在是否對皓華化學科技有些警惕。

Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At least one analyst has provided forecasts out to 2026, which can be seen for free on our platform here.

即便如此,業務的長期發展軌跡對於股東的價值創造更爲重要。至少有一位分析師提供了到2026年的預測,可以在我們的平台上免費查看。

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

尋找可能達到轉折點的有趣公司的另一種方法是使用內部人士收購的成長型公司的免費清單,跟蹤管理層是買入還是賣出。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論